Potential Therapeutic Target for Diabetes - Sirtuin Enzyme

Potential Therapeutic Target for Diabetes - Sirtuin Enzyme

by Chrisy Ngilneii on  January 27, 2018 at 4:46 PM Health Watch
RSS Email Print This Page Comment bookmark
Font : A-A+

Highlights:
  • Sirtuin enzyme (Sirt2) may be the key cause in hepatic glucokinase.
  • It may be a potential therapeutic target in type-2 diabetes treatment.
  • Hepatic glucokinase refers to abnormalities in glucose uptake by the liver
Sirt-2: Regulator of hepatic glucose uptake (HGU)
A sirtuin enzyme (Sirt2) has been identified as a key player in regulating hepatic glucokinase or hepatic glucose uptake (HGU) through modifying glucokinase regulatory protein (GKRP), suggesting that this mechanism offers a potential therapeutic target for type 2 diabetes.
Potential Therapeutic Target for Diabetes - Sirtuin Enzyme

This is the claim of a recent research led by Hiroshi Inoue from Kanazawa University, Ishikawa, and collaborators from the National Centre for Global Health and Medicine, Tokyo.

Previous reports show that the signaling molecule nicotinamide adenine dinucleotide (NAD+) governs glucose metabolism. In this paper, Inoue and colleagues used in vitro knockdown experiments to identify Sirt2 as a mediator of NAD+-dependent hepatic glucose uptake (HGU). However, Sirt2, did not influence the gene expression levels of glucokinase and glucose-6-phosphatase, thereby implying that Sirt2 affected hepatic glucose uptake (HGU) through post-translational modifications.

Glucokinase in normal and diabetic cells
In normal cells, glucokinase binds to glucokinase regulatory protein (GKRP) in low glucose conditions, while the two proteins dissociate in response to elevation of glucose levels. In cells derived from diabetic mice, however, this desolation does not take place even under high glucose concentrations. In the current study, the researchers were able to reverse this perturbation by overexpressing Sirt2 and showed that Sirt2 can regulate the dissociation by directly binding to GKRP and deacetylating it (at residue K126) in a NAD+-dependent manner.

The researchers also performed experiments in mice and found that expressing a form of GKRP that could not be acetylated perturbs HGU, suggesting that acetylation of GKRP is involved in HGU and the maintenance of normal glucose levels. Furthermore, the researchers found that a decrease in NAD+-dependent Sirt2 activity and defective Sirt2-dependent deacetylation of GKRP were responsible, at least in part, for the HGU abnormality observed in obese diabetic mice.

Overall, the results indicate that NAD+ and Sirt2 regulate HGU and that Sirt2 acts through deacetylating GKRP. The authors conclude that "these findings suggest that NAD +/Sirt2-dependent GKRP deacetylation regulation plays an important role in HGU control and that this regulation is a novel therapeutic target in type 2 diabetes and obesity and is responsible for HGU impairment."

References:
  1. Hitoshi Watanabe, Yuka Inaba et al. Sirt2 Facilitates Hepatic Glucose Uptake by Deacetylating Glucokinase Regulatory Protein, Nature Communications doi:10.1038/s41467-017-02537-6


Source-Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions
Advertisement

Related Links

More News on:

Diabetic Retinopathy Diabetes Diabetic Diet Diabetes - Essentials Diabetes - Self-Monitoring of Blood Glucose (SMBG) Insulin Delivery Devices Diabetes and Exercise Stress Relief Through Alternative Medicine Stress and the Gender Divide Silent Killer Diseases 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive

Loading...